China's medical products administrator approved Jiangsu Lianhuan Pharmaceutical (SHA:600513) subsidiary Xinxiang Changle Pharmaceutical's drug registration for its amlodipine besylate tablets for high blood pressure, according to a Friday filing with the Shanghai bourse.
The antihypertensive drug comes in 5-milligram and 10-milligram tablets, the filing said.
Shares fell 1% during late morning trading on Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments